AstraZeneca PLC (AZN) - Total Assets

Latest as of March 2026: GBX114.02 Billion GBX ≈ $13.87 Million USD

Based on the latest financial reports, AstraZeneca PLC (AZN) holds total assets worth GBX114.02 Billion GBX (≈ $13.87 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore AZN operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.

AstraZeneca PLC - Total Assets Trend (1990–2025)

This chart illustrates how AstraZeneca PLC's total assets have evolved over time, based on quarterly financial data. See AstraZeneca PLC book value and equity for net asset value and shareholders' equity analysis.

AstraZeneca PLC - Asset Composition Analysis

Current Asset Composition (December 2025)

AstraZeneca PLC's total assets of GBX114.02 Billion consist of 25.2% current assets and 74.8% non-current assets.

Asset Category Amount (GBX) % of Total Assets
Cash & Equivalents GBX0.00 5.0%
Accounts Receivable GBX16.34 Billion 14.3%
Inventory GBX6.56 Billion 5.8%
Property, Plant & Equipment GBX0.00 0.0%
Intangible Assets GBX37.85 Billion 33.2%
Goodwill GBX21.24 Billion 18.6%

Asset Composition Trend (1990–2025)

This chart illustrates how AstraZeneca PLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see AZN market cap overview.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: AstraZeneca PLC's current assets represent 25.2% of total assets in 2025, a decrease from 58.1% in 1990.
  • Cash Position: Cash and equivalents constituted 5.0% of total assets in 2025, up from 2.1% in 1990.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 51.0% of total assets, an increase from 0.0% in 1990.
  • Asset Diversification: The largest asset category is intangible assets at 33.2% of total assets.

AstraZeneca PLC Competitors by Total Assets

Key competitors of AstraZeneca PLC based on total assets are shown below.

Company Country Total Assets
Biogen Inc
NASDAQ:BIIB
USA $29.44 Billion
Virbac SA
PA:VIRP
France €1.82 Billion
Aurora Optoelectronics Co Ltd
SHG:600666
China CN¥2.22 Billion
NanJing Pharmaceutical Co Ltd
SHG:600713
China CN¥34.05 Billion
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3
Brazil R$3.66 Billion
Firebrick Pharma Ltd
AU:FRE
Australia AU$2.28 Million
Eli Lilly and Company
SA:LILY34
Brazil R$112.48 Billion
Pfizer Inc
SA:PFIZ34
Brazil R$207.62 Billion

AstraZeneca PLC - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 0.91 0.90 1.13
Quick Ratio 0.71 0.70 0.68
Cash Ratio 0.00 0.00 0.00
Working Capital GBX-2.96 Billion GBX-2.99 Billion GBX3.09 Billion

AstraZeneca PLC - Advanced Valuation Insights

This section examines the relationship between AstraZeneca PLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 6.16
Latest Market Cap to Assets Ratio 0.02
Asset Growth Rate (YoY) 9.6%
Total Assets GBX114.07 Billion
Market Capitalization $2.27 Billion USD

Valuation Analysis

Below Book Valuation: The market values AstraZeneca PLC's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.

Positive Asset Growth: AstraZeneca PLC's assets grew by 9.6% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for AstraZeneca PLC (1990–2025)

The table below shows the annual total assets of AstraZeneca PLC from 1990 to 2025.

Year Total Assets Change
2025-12-31 GBX114.07 Billion
≈ $13.88 Million
+9.65%
2024-12-31 GBX104.03 Billion
≈ $12.66 Million
+2.88%
2023-12-31 GBX101.12 Billion
≈ $12.30 Million
+4.80%
2022-12-31 GBX96.48 Billion
≈ $11.74 Million
-8.43%
2021-12-31 GBX105.36 Billion
≈ $12.82 Million
+57.90%
2020-12-31 GBX66.73 Billion
≈ $8.12 Million
+8.72%
2019-12-31 GBX61.38 Billion
≈ $7.47 Million
+1.20%
2018-12-31 GBX60.65 Billion
≈ $7.38 Million
-4.27%
2017-12-31 GBX63.35 Billion
≈ $7.71 Million
+1.32%
2016-12-31 GBX62.53 Billion
≈ $7.61 Million
+4.11%
2015-12-31 GBX60.06 Billion
≈ $7.31 Million
+2.49%
2014-12-31 GBX58.59 Billion
≈ $7.13 Million
+4.82%
2013-12-31 GBX55.90 Billion
≈ $6.80 Million
+4.42%
2012-12-31 GBX53.53 Billion
≈ $6.51 Million
+1.33%
2011-12-31 GBX52.83 Billion
≈ $6.43 Million
-5.87%
2010-12-31 GBX56.13 Billion
≈ $6.83 Million
+2.20%
2009-12-31 GBX54.92 Billion
≈ $6.68 Million
+16.98%
2008-12-31 GBX46.95 Billion
≈ $5.71 Million
-2.10%
2007-12-31 GBX47.96 Billion
≈ $5.83 Million
+60.22%
2006-12-31 GBX29.93 Billion
≈ $3.64 Million
+20.50%
2005-12-31 GBX24.84 Billion
≈ $3.02 Million
-3.17%
2004-12-31 GBX25.65 Billion
≈ $3.12 Million
+8.82%
2003-12-31 GBX23.57 Billion
≈ $2.87 Million
+9.26%
2002-12-31 GBX21.58 Billion
≈ $2.63 Million
+16.65%
2001-12-31 GBX18.50 Billion
≈ $2.25 Million
+0.27%
2000-12-31 GBX18.45 Billion
≈ $2.24 Million
-6.91%
1999-12-31 GBX19.82 Billion
≈ $2.41 Million
+7.24%
1998-12-31 GBX18.48 Billion
≈ $2.25 Million
+123.11%
1997-12-31 GBX8.28 Billion
≈ $1.01 Million
-3.28%
1996-12-31 GBX8.56 Billion
≈ $1.04 Million
+8.80%
1995-12-31 GBX7.87 Billion
≈ $957.52K
+7.54%
1994-12-31 GBX7.32 Billion
≈ $890.42K
-1.43%
1993-12-31 GBX7.42 Billion
≈ $903.30K
+19.97%
1992-12-31 GBX6.19 Billion
≈ $752.91K
-2.73%
1991-12-31 GBX6.36 Billion
≈ $774.08K
+4.27%
1990-12-31 GBX6.10 Billion
≈ $742.34K
--

About AstraZeneca PLC

LSE:AZN UK Drug Manufacturers - General
Market Cap
$2.27 Billion
GBX18.67 Trillion GBX
Market Cap Rank
#5743 Global
#12 in UK
Share Price
GBX12036.00
Change (1 day)
+2.52%
52-Week Range
GBX10922.00 - GBX15542.00
All Time High
GBX15542.00
About

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splend… Read more